CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
FIBROLEAD focuses on developing VM-313, a compound targeting fibroblasts to address chronic inflammation and fibrosis in inflammatory bowel disease (IBD). By improving treatment strategies, it aims to enhance patient outcomes and reduce disease progression.
Inflammatory bowel disease (IBD), which comprises Crohn's disease (CD) and ulcerative colitis (UC), is a growing global health challenge affecting over 6.8 million people.
Characterized by chronic inflammation leading to intestinal fibrosis, IBD significantly reduces quality of life and increases the risk of severe complications, including colon cancer.
Current treatments primarily target inflammation, and fail to address the persistent activation of inflammatory fibroblast phenotypes and the re…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
